BCL2 and metastatic malignant neoplasm: Systemic administration of the antisense oligonucleotide (ASO) targeting BCL2, augmerosen, downregulated the target BCL2 protein in metastatic cancer and, combined with standard anticancer therapy, helped resensitize patients with resistant melanoma [60].